TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indicated for IVF/ICSI in the context of assisted reproductive technology (ART)~* Follow a gonadotropin releasing hormone (GnRH) antagonist protocol, single injection of human chorionic gonadotropin (hCG) for triggering final follicular maturation and luteal support with vaginal micronized progesterone.~* Single fresh D5 embryo transfer~Exclusion Criteria:~* Frozen-thawed embryo transfer~* Donor egg in the current transfer~* More than 20 oocytes in the current controlled ovarian hyperstimulation (COH) cycle~* Serum P4 greater than 1.5 ng/mL prior to hCG administration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Nolasiban 900 mg (Type: EXPERIMENTAL): Nolasiban dispersible tablets for single oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo dispersible tablets for single oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a primary diagnosis of schizophrenia~* History of at least 1 prior episode of acute schizophrenia in the 3 years preceding screening~* History of schizophrenia requiring continuous antipsychotic treatment for at least 1 years preceding screening~* Clinically stable at the time of entry defined by at least a 4 week period of stable symptoms~Key Exclusion Criteria:~* Have an uncontrolled, unstable clinically significant medical condition~* History of suicide attempt or significant violence to others in the past 2 years~* A substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse~* Current substance abuse/dependence~* Concurrent psychiatric disorder other than schizophrenia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- asenapine (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned elective VATS lobectomy, wedge- or segmental resection. (for the subsequent biomarker study, only lobectomy is a inclusion criteria, specified in protocol amendment July 27th 2016)~* Patient has accepted to have epidural analgesia as part of the anaesthesia for the procedure.~* Informed consent is attained.~* Patient is over 18 years of age.~* Patient is mentally able to answer questionnaires included in the study.~Exclusion Criteria:~* Allergies to any of the medications used in the trial.~* History of previous peptic ulcer.~* History of chronic pain to any degree that will interfere with quantification of pain postoperatively.~* Dementia or reduced mental capacity to any degree that will interfere with quantification of pain postoperatively.~* Pregnancy.~* Contra-indications to placement of epidural catheter.~* Any concurrent cancer disease or use of immune modulating drugs (criteria added as part of a protocol amendment July 27th 2016 for a subsequent biomarkers study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Epidural analgesia (Type: ACTIVE_COMPARATOR): Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
- Placebo Epidural analgesia (Type: ACTIVE_COMPARATOR): Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women with one of genetic thrombophilia markers as factor V Leiden, prothrombin 20210A mutation, antiphospholipid antibodies, hyperhomocysteinemia and deficiencies of antithrombin, protein C, or protein S.~* pregnant women affected by HT and suffering of iron deficiency (ID) and iron deficiency anemia (IDA)~* different trimester of pregnancy~* previous miscarriage/s~* previous preterm delivery/ies~* iron disorders as iron deficiency and iron deficiency anemia are defined by the number of red blood cells \<4.000.000/mL, the hemoglobin concentration ≤ 11 g/dL, the total serum iron ≤ 30 mg/dL and serum ferritin ≤12 ng/mL.~Exclusion Criteria:~* absence of iron deficiency and iron deficiency anemia~* non-pregnant women~* uncomplicated pregnancies~* no informed consent~* other treatments of iron supplementation~* recent blood transfusion~* other concomitant diseases~* ascertained allergy to milk proteins or to iron products.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Lactoferrin treatment in HT pregnacies (Type: EXPERIMENTAL): Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
- Ferrous sulfate in HT pregnancies (Type: ACTIVE_COMPARATOR): Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features, as defined in DSM-IV-TR (296.5X) and confirmed by a structured Mini International Neuropsychiatric Interview (MINI)~Exclusion Criteria:~* Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder NOS (298.9).~* Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ziprasidone 20 and 60mg (Type: ACTIVE_COMPARATOR): For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed early invasive HER2-positive carcinoma of the breast with no evidence of residual, locally recurrent, or metastatic disease and defined as clinical Stage I to IIIC that is eligible for treatment with Herceptin~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Screening left ventricular ejection fraction (LVEF) greater than or equal to (≥) 55%~Exclusion Criteria:~* Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent~* History of other malignancy except for curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or curatively treated malignancies (other than breast cancer) where the participant has been disease-free for at least 5 years~* Past history of ductal carcinoma in situ treated with any systemic therapy or with radiation therapy to the ipsilateral breast where invasive cancer subsequently developed~* Metastatic disease~* Inadequate bone marrow, hepatic, or renal function~* Serious cardiac or cardiovascular disease including uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy~* History of severe allergic or immunological reactions, such as difficult-to-control asthma~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: SC Herceptin by Needle/Syringe (Type: EXPERIMENTAL): Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
- Cohort B: SC Herceptin by SID (Type: EXPERIMENTAL): Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females aged 21 to 35 years with regular ovulatory menstrual cycles of 21 to 45 days, with a Body Mass Index (BMI) between 18 and 30 kg/m2 who desire pregnancy.~* Subjects must be high responders, defined as subjects who have a serum anti-Müllerian hormone (AMH) ≥5 ng/mL at screening.~* Documented history of infertility (e.g., unable to conceive for at least 12 months or for at least 6 months if receiving donor sperm) with a Day 2 or Day 3 serum FSH level between 1 and 12 IU/L (inclusive), the results of which should be obtained within 6 months prior to randomization.~Exclusion Criteria:~* Known stage III-IV endometriosis (American Society for Reproductive Medicine, 2012).~* History of recurrent miscarriage not followed by a live birth (recurrent is defined as two (2) or more consecutive miscarriages).~* Previous in vitro fertilization (IVF) or assisted reproductive technology (ART) failure due to a poor response to gonadotropins. Poor response is defined as development of ≤2 mature follicles or history of 2 previous failed cycle cancellations prior to oocytes retrieval due to poor response.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- menotropin (Type: EXPERIMENTAL): menotropins for injection
- recombinant FSH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tysabri Observational Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Documented diagnosis of Relapsing Remitting Multiple Sclerosis~* The decision to treat with Tysabri must precede enrollment~* Patient must be a new Tysabri user, and must not have had more than 3 Tysabri infusions prior to enrollment~* Must have had at least one relapse in the previous year, and must satisfy locally approved therapeutic indications for Tysabri~Key Exclusion Criteria:~* History of Progressive Multifocal Leukoencephalopathy or other opportunistic infections, or an increased risk of opportunistic infections~* History of positive anti-Tysabri antibodies~* Concomitant Immunomodulatory or immunosuppressive therapy during therapy with Tysabri~* Patient immunocompromised at the time of enrollment~* Known active malignancy~* Women must not be breast feeding or pregnant, or planning to become pregnant (must use birth control unless surgically sterile)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tysabri (Type: None): According to the local prescribing information

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of advanced upper lobe predominant emphysema~* age \>/= 40 years~* clinically significant dyspnea~* failure of standard medical therapy to relieve symptoms (inhaled beta agonist and inhaled anticholinergic)~* pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 \< 45% predicted and experiencing \< 30% or 300 mL improvement using bronchodilator; TLC \> 110% predicted; RV \> 150% predicted)~* 6 Minute Walk Distance \>/= 150 m~Exclusion Criteria:~* alpha-1 protease inhibitor deficiency~* homogeneous disease~* tobacco use within 4 months of initial visit~* body mass index \< 15 kg/m2 or \> 35 kg/m2~* clinically significant asthma, chronic bronchitis or bronchiectasis~* allergy or sensitivity to procedural components~* pregnant, lactating or unwilling to use birth control if required~* prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endobronchial valve placement, airway stent placement or pleurodesis~* comorbid condition that could adversely influence outcomes~* inability to tolerate bronchoscopy under conscious sedation (or anesthesia)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLVR Treatment (Type: EXPERIMENTAL): BLVR Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient has not received Vimpat® more than 7 days prior to start of Non-Interventional Study (NIS)~* The patient must have a diagnosis of epilepsy with partial-onset seizures with or without secondary generalization~* Based on the physician's clinical judgment, it is in the patient's best interest to be prescribed adjunctive Vimpat® (ie, the decision to prescribe Vimpat® is made by the physician)~* Patient must be at least 18 years of age~* The patient must have had at least one seizure within the last 3 months prior to enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vimpat + Na Channel Blocking AED (Type: None): Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
- Vimpat + Non-Na Channel Blocking AED (Type: None): Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed advanced and/or aggressive hematologic malignancy (including myelodysplastic syndrome) that is unlikely to be cured by alternative therapies~* HLA-Matched unrelated donor; or 1-locus HLA-mismatched related or unrelated donor~* ECOG performance status 0-2~* Adequate organ function~* Able to understand and willing to sign a written informed consent document~* Agrees to practice adequate contraception per study requirements~Exclusion Criteria:~* Pregnant or breastfeeding~* Recipient of prior allogeneic or autologous stem cell transplantation~* Prior abdominal radiation therapy~* HIV-positive on combination antiretroviral therapy~* Seropositive for hepatitis B or C~* Allergies to bortezomib, boron, or mannitol~* Myocardial infarction within last 6 months, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias~* Uncontrolled bacterial, viral or fungal infections~* Seizures or history of seizures~* History of another non-hematologic malignancy unless disease-free for at least 5 years~* Uncontrolled intercurrent illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Velcade/Tac/MTX (Type: EXPERIMENTAL): Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m\^2 IV~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid~Drug: Methotrexate. Methotrexate 15 mg/m\^2 IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adults patients submitted to first transvenous implant of pacemakers, implantable cardioverter-defibrillator, or cardiac resynchronization therapy devices~* left ventricular ejection fraction ≤0.40 and/or~* previous transvenous temporary leads ipsilateral to the permanent device implant~Exclusion Criteria:~* history of venous thromboembolism~* atrial fibrillation~* coagulopathy or platelet disorder~* malignancy~* gastro-intestinal hemorrhage or active gastro-duodenal ulcer in the past 6 months~* abnormal prothrombin time (PT)or an international normalized ratio (INR) \>40%, or treated with oral anticoagulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Single daily dose of Placebo during six months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment of Malaria in Schoolchildren

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 8 to \< 14 years (boys), ≥ 8 to \< 12 years (girls)~* Student enrolled at participating school in classes 3-7~* Provision of informed consent from parent or guardian~* Provision of assent by student~Exclusion Criteria:~* Known allergy or history of adverse reaction to study medications~* Onset of menstruation (girls)~* Fever (≥ 37.5°C axillary) or history of fever in the previous 24 hours~* Evidence of severe malaria or danger signs~* Haemoglobin \< 7.0 gm/dL~* Parasite density \> 10,000/ul

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Combination of Amodiaquine +sulfadoxine-pyrimethamine (Type: ACTIVE_COMPARATOR): Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
- Dihydroartemisinin-piperaquine (Type: ACTIVE_COMPARATOR): Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
- Sulfadoxine-pyrimethamine alone (Type: ACTIVE_COMPARATOR): sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete